Drug Trial Radar · NCT07611513
Protective Efficacy , Immunogenicity and Safety of the Tetravalent Inactivated Enterovirus Vaccine (Vero Cell).
Last checked: Nov 20, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
6,000
Planned (sponsor's estimate)
Start
May 2026
Primary completion
Dec 2027
Study completion Sep 2028
Sponsor
- Lead sponsor
- Sinovac Biotech Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- May 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 6 months, up to 71 months
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This multicenter, randomized, double-blind, placebo-controlled phase IIIa clinical trial aims to evaluate the protective efficacy , immunogenicity and safety of the Tetravalent Inactivated Enterovirus Vaccine (Vero Cell) in Children aged 6 to 71 months. Participants will be randomly assigned in a 1:1 ratio to the trial group and the placebo group, receiving two doses of experimental vaccine or placebo , with a one-month interval between the two doses.
Conditions
- Hand, Foot, and Mouth Disease(HFMD)
- Herpangina
Interventions
Tetravalent Inactivated Enterovirus Vaccine (Vero Cell)Biological
Two doses are administered with a one-month interval between each dose.
PlaceboBiological
Two doses are administered with a one-month interval between each dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the protective efficacy of the investigational vaccine against HFMD caused by any serotype of EV71, CA16, CA10 and CA6 infection compared to placebo.Time frame: From day 15 after full-course vaccination to the data cutoff date when the pre-specified number of primary HFMD cases is reached (case-driven primary analysis)
- Evaluate the protective efficacy of the investigational vaccine against HFMD caused by CA6 infection compared to placebo.Time frame: From day 15 after full-course vaccination to the data cutoff date when the pre-specified number of primary HFMD cases is reached (case-driven primary analysis)From day 15 after the full-course vaccination to data cutoff date of primary analysis
- Evaluate the protective efficacy of the investigational vaccine against HFMD caused by CA16 infection compared to placebo.Time frame: From day 15 after full-course vaccination to the data cutoff date when the pre-specified number of primary HFMD cases is reached (case-driven primary analysis)
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Fujian Provincial Center for Disease Control and Prevention
Fujian, China
Henan Provincial Center for Disease Control and Prevention
Henan, China
Hubei Provincial Center for Disease Control and Prevention
Hubei, China
Sichuan Provincial Center for Disease Control and Prevention
Sichuan, China
Anhui Provincial Center for Disease Control and Prevention
Hefei, Anhui, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.